This article is a correction to:
Urine Soluble CD163 Is a Promising Biomarker for the Diagnosis and Evaluation of Lupus Nephritis
Yun-Ju Huang
Chiung-Hung Lin
Huang-Yu Yang
Shue-Fen Luo2
Chang-Fu Kuo- 1School of Medicine, Chang Gung University, Taoyuan City, Taiwan
- 2Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan City, Taiwan
- 3Division of Thoracic medicine, Chang Gung Memorial Hospital, Taoyuan City, Taiwan
- 4Division of Nephrology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan City, Taiwan
- 5Center for Artificial Intelligence in Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan
A Corrigendum on
Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis
by Huang Y-J, Lin C-H, Yang H-Y, Luo S-F and Kuo C-F (2022) 13:935700. doi: 10.3389/fimmu.2022.935700
In the published article, there was an error in Figure 2 as published. We mistakenly used Figure 1 as Figure 2. The Figure 1 describes us CD163 in urine and SLEDAI-2K in SLE patients while the Figure 2 describes usCD163/creatinine in urine and SLEDAI-2K in SLE patients. The corrected Figure 2 and its caption appear below.
FIGURE 2
Figure 2 Correlation between usCD163/creatinine in urine and SLEDAI-2K in SLE patients. The renal SLE patients with high usCD163/creatinine ratios had higher SLEDAI-2K scores compared with those with low usCD163 levels. However, no difference in SLEDAI-2K score was seen between the inactive and extrarenal SLE patients. SLEDAI-2k, Systemic Lupus Erythematosus Disease Activity Index 2000.
In the published article, there was an error in the Funding statement. Funding from Chang Gung Memorial Hospital Research Program (CMRPG3J0031) was omitted. The correct Funding statement appears below.
Funding
This study received funding from Key Development Project of Department of Science and Technology (2015C03Bd051) and Chang Gung Memorial Hospital Research Program (CMRPG3J0031).
The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Systemic lupus erythematosus, lupus nephritis, urine soluble CD163, urine biomarker, chronic kidney disease, macrophage, SLEDA
Citation: Huang Y-J, Lin C-H, Yang H-Y, Luo S-F and Kuo C-F (2022) Corrigendum: Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis. Front. Immunol. 13:1003761. doi: 10.3389/fimmu.2022.1003761
Received: 26 July 2022; Accepted: 08 August 2022;
Published: 29 August 2022.
Edited and Reviewed by:
Margaret Hibbs, Monash University, AustraliaCopyright © 2022 Huang, Lin, Yang, Luo and Kuo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chang-Fu Kuo, zandis@gmail.com